2022-08-20 高雄萬豪酒店 10F皇喜會議室 10D-2
時間主題講者座長摘要簡報
16:30 ~ 16:50
瀏覽海報時間
All
王百孚,
虞凱傑
16:50 ~ 16:54
MP06-01: Is extraperitoneal extended pelvic lymph node dissection adequate during robotic assisted radical prostatectomy for intermediate and high risk localized prostate cancer?
洪紹綸
王百孚,
虞凱傑
16:54 ~ 16:58
MP06-02: A single center experience of Abiraterone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel based chemotherapy
蘇楷森
王百孚,
虞凱傑
16:58 ~ 17:02
MP06-03: Real world experience of androgen deprivation therapy associated bone fracture risk in newly diagnosed prostate cancer patients
陳韋辰
王百孚,
虞凱傑
17:02 ~ 17:06
MP06-04: Hyperforin induces extrinsic/intrinsic apoptosis signaling and inhibits NF-кB for metastasis suppression in prostate cancer cells
廖丞晞
王百孚,
虞凱傑
17:06 ~ 17:10
MP06-05: Retzius-sparing robot-assisted radical prostatectomy and extended pelvic lymph node dissection for very high-risk prostate cancer
林威宇
王百孚,
虞凱傑
17:10 ~ 17:14
MP06-06: The analysis of concordance rates between cancer stage of MR/US fusion prostate biopsy and radical prostatectomy specimen
康庭碩
王百孚,
虞凱傑
17:14 ~ 17:18
MP06-07: Oncological and functional outcomes in high risk and very high risk prostate cancer patients receiving robotic-assisted radical prostatectomy
陳維心
王百孚,
虞凱傑
17:18 ~ 17:22
MP06-08: Treatment strategy and systemic review with PSMA PET/CT scan in progressive advanced prostate cancer
謝博彥
王百孚,
虞凱傑
17:22 ~ 17:26
MP06-09: KCGMH experience and meta-analysis: 6-cycle complete rate of Radium-223 therapy in mCRPC patients with different treatment sequences
江品葭
王百孚,
虞凱傑
17:26 ~ 17:30
MP06-10: Characteristics of mCRPC patients received Abiraterone acetate plus prednisolone and Enzalutamide before chemotherapy
林晏頎
王百孚,
虞凱傑